Pure Global
NCT05023343

Transmucular Quadratus Lumborum Block: Potential Quadriceps Muscle Weakness

Does Administration of the Transmuscular Quadratus Lumborum Block Cause Quadriceps Muscle Weakness: A Randomised, Double-blinded Volunteer Study
Zealand University Hospital·Phase 4·ClinicalTrials.gov·drugCompleted
View on ClinicalTrials.gov →
Study focus
Disease/Condition
Neuromuscular Blockade
Drug/Device/Intervention
Ropivacaine
Study type
Interventional
Intervention type
drug
Sponsor & location
Primary sponsor
Zealand University Hospital
Location
Roskilde, Denmark
Timeline & enrollment
Phase
Phase 4
Start date
Oct 02, 2021
End date
Nov 28, 2021
Enrollment
20 participants
Primary outcome

Maximum unilateral knee extension strength

Summary

The aim of this study is to examine whether the administration of the TQL block cause motor
 block of the lumbar plexus and thereby quadriceps muscle weakness. The investigators
 hypothesise that the administration of a unilateral TQL block does not cause quadriceps
 muscle weakness compared to a placebo block.

ICD-10 classifications
Skeletal muscle relaxants [neuromuscular blocking agents]Poisoning: Skeletal muscle relaxants [neuromuscular blocking agents]Other neuromuscular dysfunction of bladderNeuromuscular dysfunction of bladder, unspecifiedNeuromuscular scoliosis
Data source
Registry
ClinicalTrials.gov
Trial ID
NCT05023343
Type
Non-Device Trial
About this record

Access comprehensive clinical trial information for NCT05023343 through Pure Global AI's free database. This Phase 4 trial is sponsored by Zealand University Hospital and is currently Completed. The study focuses on Neuromuscular Blockade. Target enrollment is 20 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.